King-Jones Heidy bought SYRE
October 1, 2026 · Form 4 insider transaction
King-Jones Heidy bought 28,933 shares of Spyre Therapeutics, Inc. at $14.50 per share, a transaction worth $419.5K. The trade was recorded as option exercise under a pre-scheduled Rule 10b5-1 plan and disclosed on an SEC Form 4, filed 1 day after the transaction.
Direction
Acquired (buy-side)
Shares
28,933
Price
$14.50
Total value
$419.5K
InsiderKing-Jones Heidy
Role—
SecurityCommon Stock
Transaction codeM: Option exercise
Transaction dateOctober 1, 2026
Filing dateOctober 2, 2026
Shares owned after31,778
OwnershipDirect
10b5-1 planYes
AmendedNo
Footnotes
This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026.